| Medicine |
Indication |
| alirocumab |
Hypercholesterolaemia and elevated (atherosclerotic) cardiovascular risk |
| atomoxetine |
Attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older |
| azathioprine |
For the treatment of adults with inflammatory rheumatic, bowel and skin diseases |
| aztreonam lysine (Cayston) |
Suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older |
| bempedoic acid |
Primary hypercholesterolaemia or mixed dyslipidaemia, where maximally-tolerated lipid-lowering therapy has failed to achieve target LDL cholesterol |
| buprenorphine |
Maintenance treatment of opioid dependence |
| ciclosporin (Capimune) |
Inflammatory rheumatic and skin conditions |
| ciclosporin (Neoral) |
Solid organ transplant in adult patients |
| cinacalcet |
Secondary hyperparathyroidism in patients with end stage renal disease on dialysis |
| colistimethate sodium |
Chronic pulmonary Pseudomonas aeruginosa infection in children and adults with cystic fibrosis and adults with non-cystic fibrosis bronchiectasis |
| dexamfetamine and lisdexamfetamine |
Attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older |
| dornase alfa |
Management of cystic fibrosis patients with a forced vital capacity (FVC) of greater than 40% of predicted and over 5 years of age to improve pulmonary function |
| entecavir |
Chronic hepatitis B infection (adults) |
| Erythropoiesis Stimulating Agents (ESAs) |
Chronic renal failure |
| evolocumab |
Hypercholesterolaemia and elevated (atherosclerotic) cardiovascular risk |
| Feminising endocrine treatment (Estradiol and GnRHa) |
Gender dysphoria/incongruence after assessment at the GIC for over 18 year olds |
| guanfacine |
Attention deficit hyperactivity disorder (ADHD) in children aged 6 to 17 years and older |
| hydroxycarbamide |
Myeloproliferative neoplasms including essential thrombocythaemia, polycythaemia vera, myelofibrosis and chronic myelomonocytic leukaemia |
| hydroxychloroquine |
Inflammatory rheumatic diseases |
| ketamine |
Complex pain in palliative care patients |
| lanreotide long acting and octreotide long acting (somatostatin analogues) |
Acromegaly
|
| lanreotide and octreotide (somatostatin analogues) |
Neuroendocrine tumours |
| leflunomide |
Inflammatory rheumatic diseases |
| liraglutide |
Weight loss |
| Masculinising endocrine treatment (Testosterone) |
Gender dysphoria/incongruence after assessment at the GIC for over 18 year olds |
| mercaptopurine |
Inflammatory bowel disease (ulcerative colitis and Crohn’s disease) |
| methotrexate (oral and subcutaneous) |
Adults with inflammatory rheumatic, bowel and skin conditions |
| methotrexate (oral and subcutaneous) |
Paediatric inflammatory rheumatic and bowel conditions |
| methylphenidate |
Attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 and older |
| mexiletine |
Ventricular arrhythmias |
| mycophenolate mofetil (MMF) and mycophenolic acid (Myfortic) |
Solid organ transplant adult patients |
| mycophenolate mofetil (MMF) |
For non-transplant indications |
| mycophenolic acid |
Uveitis |
| penicillamine |
Inflammatory rheumatic diseases |
| riluzole |
Amyotrophic lateral sclerosis (ALS) motor neurone disease |
| roxadustat |
Management of symptomatic anaemia in patients with chronic renal failure |
| somatropin (recombinant human growth hormone) |
Adult hypopituitarism |
| somatropin (recombinant human growth hormone) |
Growth failure/disturbance in children |
| sulfasalazine |
Inflammatory rheumatic diseases |
| tacrolimus (Adoport, Prograf, Dailiport, Advagraf) |
Solid organ transplants in adult patients |
| tacrolimus |
Uveitis |
| tenofovir disoproxil fumarate |
Chronic hepatitis B infection in adults |
| tobramycin |
Chronic pulmonary Pseudomonas Aeruginosa infection in children and adults with cystic fibrosis |
| valganciclovir |
Prevention of CMV infection in solid organ transplant |